Michalis V Karamouzis
Overview
Explore the profile of Michalis V Karamouzis including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
143
Citations
6530
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bousou T, Sarantis P, Anastasiou I, Trifylli E, Liapopoulos D, Korakaki D, et al.
Cancers (Basel)
. 2025 Feb;
17(3).
PMID: 39941920
Cholangiocarcinoma is a rare primary liver cancer with poor prognosis, due to the advanced stage at the time of diagnosis and limited therapeutic options, with poor response. Chemotherapy remains the...
2.
Hasemaki N, Vailas M, Vergadis C, Sotiropoulou M, Anastasiou I, Sarlanis H, et al.
Prz Gastroenterol
. 2025 Jan;
19(3):337-343.
PMID: 39802964
No abstract available.
3.
Katifelis H, Grammatikaki S, Zakopoulou R, Bamias A, Karamouzis M, Stravodimos K, et al.
In Vivo
. 2024 Dec;
39(1):146-151.
PMID: 39740865
Background/aim: Clear cell renal cell carcinoma (ccRCC) represents the most common type of renal cancer. When resectable, nephrectomy is the only radical treatment for ccRCC, however metastasis is already present...
4.
Anastasiou I, Sarantis P, Rebelos E, Eleftheriadou I, Tentolouris K, Katsaouni A, et al.
J Biochem Mol Toxicol
. 2024 Oct;
38(11):e70036.
PMID: 39467148
Accumulating evidence has shown that l-securinine can, in certain circumstances, suppress tumor development by elevating reactive oxygen species (ROS) levels. The current work set out to examine l-securinine's apoptotic effects...
5.
Mihailidou C, Papakotoulas P, Papavassiliou A, Karamouzis M
Oncotarget
. 2024 Jul;
15:461.
PMID: 38985135
No abstract available.
6.
Fioretzaki R, Sarantis P, Charalampakis N, Christofidis K, Mylonakis A, Koustas E, et al.
Biomedicines
. 2024 Apr;
12(4).
PMID: 38672239
Defining predictive biomarkers for targeted therapies and optimizing anti-tumor immune response is a main challenge in ongoing investigations. Progastrin has been studied as a potential biomarker for detecting and diagnosing...
7.
Dovrolis N, Katifelis H, Grammatikaki S, Zakopoulou R, Bamias A, Karamouzis M, et al.
Cancers (Basel)
. 2023 Dec;
15(23).
PMID: 38067341
Clear cell renal cell carcinoma (ccRCC) is the most common renal cancer. Despite the rapid evolution of targeted therapies, immunotherapy with checkpoint inhibition (ICI) as well as combination therapies, the...
8.
Anastasiou I, Sarantis P, Eleftheriadou I, Tentolouris K, Mourouzis I, Karamouzis M, et al.
Int J Low Extrem Wounds
. 2023 Nov;
:15347346231212332.
PMID: 37956650
Introduction: Wound healing is a dynamic process that begins with inflammation, proliferation, and cell migration of a variety of fibroblast cells. As a result, identifying possible compounds that may improve...
9.
Fakih M, Salvatore L, Esaki T, Modest D, Lopez-Bravo D, Taieb J, et al.
N Engl J Med
. 2023 Oct;
389(23):2125-2139.
PMID: 37870968
Background: G12C is a mutation that occurs in approximately 3 to 4% of patients with metastatic colorectal cancer. Monotherapy with KRAS G12C inhibitors has yielded only modest efficacy. Combining the...
10.
Vallilas C, Papadakos S, Androutsakos T, Pergaris A, Sarantis P, Apostolidi E, et al.
Am J Case Rep
. 2023 Oct;
24:e939862.
PMID: 37812585
BACKGROUND Desmoid tumors are a fibroblastic proliferation of soft tissues, with an extreme inclination for local dissemination and recurrence. Surgical excision is the usual treatment choice, with data regarding pharmaceutical...